These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 30348204)
1. Production of a mono-biotinylated EGFR nanobody in the E. coli periplasm using the pET22b vector. Noor A; Walser G; Wesseling M; Giron P; Laffra AM; Haddouchi F; De Grève J; Kronenberger P BMC Res Notes; 2018 Oct; 11(1):751. PubMed ID: 30348204 [TBL] [Abstract][Full Text] [Related]
2. A camelid nanobody against EGFR was easily obtained through refolding of inclusion body expressed in Escherichia coli. Xu L; Song X; Jia L Biotechnol Appl Biochem; 2017 Nov; 64(6):895-901. PubMed ID: 28853185 [TBL] [Abstract][Full Text] [Related]
3. Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies. Tintelnot J; Baum N; Schultheiß C; Braig F; Trentmann M; Finter J; Fumey W; Bannas P; Fehse B; Riecken K; Schuetze K; Bokemeyer C; Rösner T; Valerius T; Peipp M; Koch-Nolte F; Binder M Mol Cancer Ther; 2019 Apr; 18(4):823-833. PubMed ID: 30824613 [TBL] [Abstract][Full Text] [Related]
4. Preparation and characterization of humanized nanobodies targeting the dimer interface of epidermal growth factor receptor (EGFR). Zhu H; Zhao L; Li Z; Wen B; Qiu C; Liu M; Xu Z; Hu S; Li H Protein Expr Purif; 2019 May; 157():57-62. PubMed ID: 30735705 [TBL] [Abstract][Full Text] [Related]
5. Streptavidin-biotin-based directional double Nanobody sandwich ELISA for clinical rapid and sensitive detection of influenza H5N1. Zhu M; Gong X; Hu Y; Ou W; Wan Y J Transl Med; 2014 Dec; 12():352. PubMed ID: 25526777 [TBL] [Abstract][Full Text] [Related]
6. Affinity enhancement of nanobody binding to EGFR: in silico site-directed mutagenesis and molecular dynamics simulation approaches. Farasat A; Rahbarizadeh F; Hosseinzadeh G; Sajjadi S; Kamali M; Keihan AH J Biomol Struct Dyn; 2017 Jun; 35(8):1710-1728. PubMed ID: 27691399 [TBL] [Abstract][Full Text] [Related]
7. A comparative study and evaluation of anti-EGFR nanobodies expressed in Pichia pastoris and Escherichia coli as antitumor moieties. Xi X; Sun W; Li H; Fan Q; Zhang X; Sun F Protein Expr Purif; 2021 Aug; 184():105888. PubMed ID: 33857600 [TBL] [Abstract][Full Text] [Related]
8. Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody. Omidfar K; Amjad Zanjani FS; Hagh AG; Azizi MD; Rasouli SJ; Kashanian S Mol Biol Rep; 2013 Dec; 40(12):6737-45. PubMed ID: 24052234 [TBL] [Abstract][Full Text] [Related]
9. Molecular and functional insight into anti-EGFR nanobody: Theranostic implications for malignancies. Tripathy RK; Pande AH Life Sci; 2024 May; 345():122593. PubMed ID: 38554946 [TBL] [Abstract][Full Text] [Related]
10. Development and evaluation of a single domain antibody against human epidermal growth factor receptor (EGFR). Ahdi Khosroshahi S; Farajnia S; Ghiamirad M; Tanomand A; Veisi K; Rahbarnia L; Akbari B Protein Expr Purif; 2016 Apr; 120():59-64. PubMed ID: 26690373 [TBL] [Abstract][Full Text] [Related]
11. Streamlined method for parallel identification of single domain antibodies to membrane receptors on whole cells. Rossotti M; Tabares S; Alfaya L; Leizagoyen C; Moron G; González-Sapienza G Biochim Biophys Acta; 2015 Jul; 1850(7):1397-404. PubMed ID: 25819371 [TBL] [Abstract][Full Text] [Related]
12. Expression, purification and characterization of in vivo biotinylated dengue virus envelope domain III based tetravalent antigen. Batra G; Talha SM; Nemani SK; Dhar N; Swaminathan S; Khanna N Protein Expr Purif; 2010 Nov; 74(1):99-105. PubMed ID: 20435144 [TBL] [Abstract][Full Text] [Related]
13. Cytoplasmic versus periplasmic expression of site-specifically and bioorthogonally functionalized nanobodies using expressed protein ligation. Billen B; Vincke C; Hansen R; Devoogdt N; Muyldermans S; Adriaensens P; Guedens W Protein Expr Purif; 2017 May; 133():25-34. PubMed ID: 28238765 [TBL] [Abstract][Full Text] [Related]
14. Biotinylated bionanocapsules for displaying diverse ligands toward cell-specific delivery. Shishido T; Azumi Y; Nakanishi T; Umetsu M; Tanaka T; Ogino C; Fukuda H; Kondo A J Biochem; 2009 Dec; 146(6):867-74. PubMed ID: 19710034 [TBL] [Abstract][Full Text] [Related]
15. Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody". Sharifi J; Khirehgesh MR; Akbari B; Soleymani B; Mansouri K Mol Biotechnol; 2021 Jun; 63(6):525-533. PubMed ID: 33772436 [TBL] [Abstract][Full Text] [Related]
17. High affinity nanobodies against human epidermal growth factor receptor selected on cells by E. coli display. Salema V; Mañas C; Cerdán L; Piñero-Lambea C; Marín E; Roovers RC; Van Bergen En Henegouwen PM; Fernández LÁ MAbs; 2016 Oct; 8(7):1286-1301. PubMed ID: 27472381 [TBL] [Abstract][Full Text] [Related]
18. Secretory production of a camelid single-domain antibody (VHH, nanobody) by the Serratia marcescens Lip system in Escherichia coli. Asada T; Takagi D; Nakai M; Abe S; Yuasa K Biochem Biophys Res Commun; 2021 Apr; 549():105-112. PubMed ID: 33667707 [TBL] [Abstract][Full Text] [Related]
19. Enzymatic ligation of an antibody and arginine 9 peptide for efficient and cell-specific siRNA delivery. Ando Y; Nakazawa H; Miura D; Otake M; Umetsu M Sci Rep; 2021 Nov; 11(1):21882. PubMed ID: 34750461 [TBL] [Abstract][Full Text] [Related]
20. Screening, expression and anti-tumor functional identification of anti-LAG-3 nanobodies. Jiang D; Chen R; Wang L; Xu G Protein Expr Purif; 2024 Oct; 222():106522. PubMed ID: 38851552 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]